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We report the case of a 56-year-old female who presented with symptomatic paroxysmal atrial ﬁbril-
lation. Anamnestic heparin-induced thrombocytopenia (HIT) type II was suspected, and a rapid diag-
nostic test showed antibodies against platelet factor 4. The heparin-induced platelet activation-assay was
negative. Radiofrequency pulmonary vein isolation with intraprocedural anticoagulation using bivalir-
udin was ultimately performed. Dosing was controlled by monitoring the activated clotting time. Post-
procedural blood tests were normal. There were no thromboembolic or bleeding events. Bivalirudin is a
therapeutic option for anticoagulation during pulmonary vein isolation procedures in patients with a
history of HIT type II.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Case report
1.1. History
We report the case of a 56-year-old female who presented with
symptomatic paroxysmal atrial ﬁbrillation. Anamnestic heparin-
induced thrombocytopenia (HIT) type II was suspected, and a HIT
diagnostic test was performed. The initial diagnosis of HIT II was
made in 2006. A rapid test showed antibodies against platelet
factor 4. The heparin-induced platelet activation assay was nega-
tive. The patient was on oral Apixaban (5 mg 1-0-1) for antic-
oagulation, and also metoprolol (95 mg 1-0-1). Relevant history
included single-vessel coronary disease with moderately reduced
systolic pump function, and a stroke without residual symptoms.
After extensive consideration, radiofrequency pulmonary vein
isolation with intraprocedural anticoagulation using bivalirudin
was ultimately performed.blished by Elsevier B.V. All rights
gy, Charité Berlin Campus Ben-
many. Tel.: þ49 30 8445 4782;
ellmann).1.2. Treatment and course
Laboratory parameters normalized after the patient was hos-
pitalized (Table 1). Oral anticoagulation with Apixaban was stop-
ped the day before the planned procedure. At the beginning of
pulmonary vein isolation after transseptal puncture, bivalirudin
was administered as a 0.75 mg/kg intravenous bolus, followed by a
1.75 mg/kg/h infusion. The activated clotting time was subse-
quently closely monitored. The values tended to be high, but the
infusion rate was maintained (Table 2). The planned radio-
frequency pulmonary vein isolation was performed successfully
without complications after 3-dimensional mapping of the pul-
monary veins and left atrium. There was no post-interventional
pericardial effusion. Bivalirudin was stopped immediately after the
ﬁnal radiofrequency application. No bleeding or clotting events
were noted. The laboratory values remained stable before and
after ablation (Table 1). After ablation, a direct and uncomplicated
conversion to oral anticoagulation with Apixaban (5 mg 1-0-1)
was performed. The patient was discharged home on the third
postoperative day.
1.3. Discussion
Bivalirudin is a direct thrombin inhibitor that overcomes many
limitations seen with indirect thrombin inhibitors, such as
heparin. It is a short, synthetic peptide that is a reversible inhibitorreserved.
Table 1
The laboratory values remained stable before and after ablation. The laboratory test
results are consistently normal values without abbreviations.
One day before
ablation
One day after
ablation
Three days after
ablation
Hemoglobin (g/dl) 14.7 14.8 14.0
Hematocrit (l/l) 0.450 0.440 0.400
Platelets (/nl) 189 195 180
INR 1.14 1.08 1.08
Quick (%) 81 89 87
Table 2
The activated clotting time and infusion rate of bivalirudin during pulmonary vein
isolation. The infusion of bivalirudin was started after uncomplicated transseptal
puncture.
Time (min) Activated clotting
time
Bivalirudin infusion rate
0 Eliminates 0.75 mg/kg intravenous bolus, followed by
a 1.75 mg/kg/h infusion
10 607 s 175 mg/kg/h
20 463 s 175 mg/kg/h
40 595 s 175 mg/kg/h
60 496 s 175 mg/kg/h
80 528 s 175 mg/kg/h
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rapid onset of action with a plasma half-life of 25 min. It inhibits
circulating and clot-bound thrombin, while also inhibiting
thrombin-mediated platelet activation and aggregation. It does not
bind to plasma proteins (other than thrombin) or to red blood
cells. Therefore, it has a predictable antithrombotic response. It
does not need a binding cofactor such as antithrombin. Bivalirudin
does not activate platelets. Current studies recommend using
bivalirudin as a preferred alternative to unfractionated heparin in
patients with HIT for cardiac and vascular surgery as well as for
percutaneous coronary intervention [1]. Anticoagulation for
radiofrequency pulmonary vein isolation may be another potential
use for bivalirudin in the setting of HIT. Ablation of pulmonary
veins is an established therapeutic option for patients with
symptomatic drug-refractory paroxysmal atrial ﬁbrillation.
Radiofrequency is currently the most widely used source of energy
for pulmonary vein ablation. Our usual activated clotting time
(ACT) values in radiofrequency procedures are above 350 s. The
initial ACT value in this procedure was 4500 s; we thought this
was due to the initial bolus. Although the ACT value throughout
the procedure was higher than the usual 350 s, we maintained the
infusion rate to avoid ﬂuctuations below 350 s. Despite lacking
experience in the use of bivalirudin for radiofrequency pulmonary
vein isolation, we tried not to undershoot our ACT target. We felt
supported in this intraprocedural anticoagulation management by
the fact that there were no bleeding or thrombotic complications.
Anticoagulation is required during this procedure, since stroke risk
is a feared complication of radiofrequency pulmonary vein isola-
tion [2]. There are a few reports in the literature about the use of
bivalirudin during electrophysiology procedures [3]; As in our
case, bivalirudin was administered as a 0.75 mg/kg intravenous
bolus, followed by a 1.75 mg/kg/h infusion. ACT was monitored
closely during pulmonary vein isolation. There were no bleedingcomplications, although the ACT was intermittently increased
(Table 2). To avoid ﬂuctuations in a non-therapeutic range, the
infusion rate was not lowered. The ACT is the most commonly
used functional test to measure heparin anticoagulation. This test
is based on the ability of whole blood to form a visible ﬁbrin
monomer within a glass tube. However, this procedure has known
limitations. It is imprecise, and the sensitivity is in the lower
range; thus, this method of measurement is of limited clinical use,
in particular for the monitoring of hirudin and other direct
thrombin inhibitors. Most recently, the direct prothrombin path-
way has predominated for monitoring of direct thrombin inhibi-
tors, as with determination of the ecarin clotting time. However,
this is not always immediately and directly available. Moreover,
Weeks et al. reported that hyper-ACT responses to bivalirudin
therapy in percutaneous coronary intervention were not asso-
ciated with elevated bleeding risk [4]. There were no throm-
boembolic events and the laboratory values remained stable
before and after ablation (Table 1). After ablation, a prompt and
uncomplicated conversion to oral anticoagulation with Apixaban
(5 mg 1-0-1) was performed.
1.4. Summary
This case shows that the treatment of patients with rhythmo-
logical concerns who have actual or suspected HIT II can be very
complex. Bivalirudin is a therapeutic option for anticoagulation
during pulmonary vein isolation procedures in patients with a
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